$CUE

Ray Sumita sold $266K of CUE

Ray Sumita (Chief Legal Compliance Officer) sold 8,829 shares of Cue Biopharma, Inc. (CUE) at an average of $30.09 ($29.37–$31.13, $0.27M total) across 3 trades on 2026-08-13.

Original reporting
SEC EDGAR · Ray Sumita
Published Aug 17, 2026, 10:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 10:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CUE
Neutral
high confidence
Mentioned
$CUE
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CUENeutralLow
01

Why it matters

The newest fact is the disclosed sale of 8,829 shares for about $265.6k, with post-transaction holdings of 118,545 shares.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not provide a fundamental catalyst.

03

What to watch

Insider sales are often planned for liquidity and do not necessarily reflect negative expectations; the filing lacks any accompanying narrative or company event.

Relevance 4/10Novelty 4/10Timing: filed 2026-08-17 after-hours; transaction dated 2026-08-13

Background

This is an SEC Form 4 insider transaction disclosure for Cue Biopharma, Inc., reported by Chief Legal Compliance Officer Ray Sumita.

Company-level read

Ticker impact

$CUENeutralHigh confidence
Context

Cue Biopharma disclosed a Form 4 showing officer Ray Sumita sold $265,627.93 of CUE shares in open-market trades on 2026-08-13.

Expected impact

Likely limited near-term impact; treat as low-signal unless paired with other disclosures.

Evidence & confidence

The article provides only the transaction details (size, dates, prices) and notes no 10b5-1 plan, but it does not include any new operational, regulatory, or financial catalyst.

Market effects

No sector-wide implication is provided; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted as discretionary selling, which some traders may read as caution.

Key entities

  • Cue Biopharma, Inc.

    US-listed biotech issuer subject of the Form 4 insider sale disclosure.

  • Ray Sumita

    Chief Legal Compliance Officer who sold shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CUEMed

Cue Biopharma, Inc. (CUE): Results of Operations and Financial Condition

Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cue-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applications • Completed a $50 mill

$CUEMedAI 8/10

Cue Biopharma Announces $50.0 Million Private Placement

Cue Biopharma (Nasdaq: CUE) announced a $50.0 million private placement. It will sell 1,418,071 common shares at $33.21 each and issue pre-funded warrants for up to 87,500 shares at $33.209 per warrant, with a $0.001 exercise price. Closing is expected around July 13, 2026. Proceeds will fund clinical development and general corporate purposes.

$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin

$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare biotech gainers on Tuesday included Bluejay Diagnostics (BJDX), which said it signed a strategic partnership with Argonaut to support its Symphony near-patient diagnostic platform; BJDX shares rose 100% to $4.34 and the company also announced a private placement up to $23.6M. Picard Medical (PMI) reported completed animal implant studies for its next-gen Emperor total artificial heart; shares rose 60.33% to $0.27. Legend Biotech (LEGN) said it will present Phase 1 data for LB2501 show